{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:10:44Z","timestamp":1793970644581,"version":"4.8.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The coronavirus (COVID-19) pandemic, caused by severe acute respiratory system coronavirus 2 (SARS-CoV-2), has created significant challenges for scientists seeking to understand the pathogenic mechanisms of SARS-CoV-2 infection and to identify the best therapies for infected patients. Although ACE2 is a known receptor for the virus and has been shown to mediate viral entry into the lungs, accumulating reports highlight the presence of neurological symptoms resulting from infection. As ACE2 expression is low in the central nervous system (CNS), these neurological symptoms are unlikely to be caused by ACE2-virus binding. In this review, we will discuss a proposed interaction between SARS-CoV-2 and Toll-like receptor 2 (TLR2) in the CNS. TLR2 is an innate immune receptor that recognizes exogenous microbial components but has also been shown to interact with multiple viral components, including the envelope (E) protein of SARS-CoV-2. In addition, TLR2 plays an important role in the pathogenesis of neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD). Based on these observations, we hypothesize that TLR2 may play a critical role in the response to SARS-CoV-2 infiltration in the CNS, thereby resulting in the induction or acceleration of AD and PD pathologies in patients.<\/jats:p>","DOI":"10.1038\/s12276-022-00755-7","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T07:04:43Z","timestamp":1649401483000},"page":"447-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS"],"prefix":"10.1038","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-1951","authenticated-orcid":false,"given":"Marcell P.","family":"Szabo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyo","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avindra","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9936-8195","authenticated-orcid":false,"given":"Changyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"755_CR1","unstructured":"World Health Organization WHO Coronavirus Dashboard, https:\/\/covid19.who.int (2021)."},{"key":"755_CR2","unstructured":"Centers for Disease Control and Prevention COVID-19, https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html (2021)."},{"key":"755_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","volume":"551","author":"E Seyed Hosseini","year":"2020","unstructured":"Seyed Hosseini, E. et al. The novel coronavirus Disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology 551, 1\u20139 (2020).","journal-title":"Virology"},{"key":"755_CR4","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","volume":"279","author":"SK Wong","year":"2004","unstructured":"Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279, 3197\u20133201 (2004).","journal-title":"J. Biol. Chem."},{"key":"755_CR5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3906\/sag-2004-168","volume":"50","author":"A Tufan","year":"2020","unstructured":"Tufan, A., Avanoglu Guler, A. & Matucci-Cerinic, M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk. J. Med. Sci. 50, 620\u2013632 (2020).","journal-title":"Turk. J. Med. Sci."},{"key":"755_CR6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00415-020-10070-8","volume":"268","author":"L Ferini-Strambi","year":"2021","unstructured":"Ferini-Strambi, L. & Salsone, M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J. Neurol. 268, 409\u2013419 (2021).","journal-title":"J. Neurol."},{"key":"755_CR7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-021-00850-3","volume":"13","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Network medicine links SARS-CoV-2\/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimer\u2019s Res. Ther. 13, 110 (2021).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"755_CR8","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/alz.12296","volume":"17","author":"Q Wang","year":"2021","unstructured":"Wang, Q., Davis, P. B., Gurney, M. E. & Xu, R. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimer\u2019s Dement. 17, 1297\u20131306 (2021).","journal-title":"Alzheimer\u2019s Dement."},{"key":"755_CR9","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3390\/brainsci11121654","volume":"11","author":"L Krey","year":"2021","unstructured":"Krey, L., Huber, M. K., Hoglinger, G. U. & Wegner, F. Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson\u2019s Disease? Brain Sci. 11, 1654 (2021).","journal-title":"Brain Sci."},{"key":"755_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jalz.2018.06.3063","volume":"15","author":"KA Matthews","year":"2019","unstructured":"Matthews, K. A. et al. Racial and ethnic estimates of Alzheimer\u2019s disease and related dementias in the United States (2015-2060) in adults aged >\/=65 years. Alzheimer\u2019s Dement. 15, 17\u201324 (2019).","journal-title":"Alzheimer\u2019s Dement."},{"key":"755_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras, C. et al. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinson\u2019s Dis. 4, 21 (2018).","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"755_CR12","doi-asserted-by":"crossref","first-page":"101208","DOI":"10.1016\/j.arr.2020.101208","volume":"65","author":"A John","year":"2021","unstructured":"John, A. & Reddy, P. H. Synaptic basis of Alzheimer\u2019s disease: focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res. Rev. 65, 101208 (2021).","journal-title":"Ageing Res. Rev."},{"key":"755_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","volume":"6","author":"JM Beitz","year":"2014","unstructured":"Beitz, J. M. Parkinson\u2019s disease: a review. Front. Biosci. Scholar Ed. 6, 65\u201374 (2014).","journal-title":"Front. Biosci. Scholar Ed."},{"key":"755_CR14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fphar.2020.00356","volume":"11","author":"M Gomez-Benito","year":"2020","unstructured":"Gomez-Benito, M. et al. Modeling Parkinson\u2019s Disease With the Alpha-Synuclein Protein. Front. Pharmacol. 11, 356 (2020).","journal-title":"Front. Pharmacol."},{"key":"755_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2012.00079","volume":"3","author":"L Oliveira-Nascimento","year":"2012","unstructured":"Oliveira-Nascimento, L., Massari, P. & Wetzler, L. M. The Role of TLR2 in Infection and Immunity. Front. Immunol. 3, 79 (2012).","journal-title":"Front. Immunol."},{"key":"755_CR16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.4049\/jimmunol.1101121","volume":"188","author":"S Liu","year":"2012","unstructured":"Liu, S. et al. TLR2 is a primary receptor for Alzheimer\u2019s amyloid beta peptide to trigger neuroinflammatory activation. J. Immunol. 188, 1098\u20131107 (2012).","journal-title":"J. Immunol."},{"key":"755_CR17","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim, C. et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).","journal-title":"Nat. Commun."},{"key":"755_CR18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5607\/en.2019.28.5.547","volume":"28","author":"S Kwon","year":"2019","unstructured":"Kwon, S., Iba, M., Masliah, E. & Kim, C. Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies. Exp. Neurobiol. 28, 547\u2013553 (2019).","journal-title":"Exp. Neurobiol."},{"key":"755_CR19","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1172\/JCI96209","volume":"128","author":"SB Rangasamy","year":"2018","unstructured":"Rangasamy, S. B. et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer\u2019s pathology. J. Clin. Investig. 128, 4297\u20134312 (2018).","journal-title":"J. Clin. Investig."},{"key":"755_CR20","volume":"17","author":"N Lax","year":"2020","unstructured":"Lax, N., Fainstein, N., Nishri, Y., Ben-Zvi, A. & Ben-Hur, T. Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer\u2019s disease mice. J. Neuroinflammation 17, 55 (2020).","journal-title":"J. Neuroinflammation"},{"key":"755_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol. Neurodegener. 13, 43 (2018).","journal-title":"Mol. Neurodegener."},{"key":"755_CR22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323, 1061\u20131069 (2020).","journal-title":"JAMA"},{"key":"755_CR23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pediatrneurol.2020.04.013","volume":"109","author":"GN McAbee","year":"2020","unstructured":"McAbee, G. N., Brosgol, Y., Pavlakis, S., Agha, R. & Gaffoor, M. Encephalitis Associated with COVID-19 Infection in an 11-Year-Old Child. Pediatr. Neurol. 109, 94 (2020).","journal-title":"Pediatr. Neurol."},{"key":"755_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2020.03.062","volume":"94","author":"T Moriguchi","year":"2020","unstructured":"Moriguchi, T. et al. A first case of meningitis\/encephalitis associated with SARS-Coronavirus-2. Int. J. Infect. Dis. 94, 55\u201358 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"755_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","volume":"191","author":"C Lodigiani","year":"2020","unstructured":"Lodigiani, C. et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb. Res. 191, 9\u201314 (2020).","journal-title":"Thromb. Res."},{"key":"755_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nan.12667","volume":"47","author":"S Al-Sarraj","year":"2021","unstructured":"Al-Sarraj, S. et al. Invited review: the spectrum of neuropathology in COVID-19. Neuropathol. Appl. Neurobiol. 47, 3\u201316 (2021).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"755_CR27","doi-asserted-by":"crossref","first-page":"e20202135","DOI":"10.1084\/jem.20202135","volume":"218","author":"E Song","year":"2021","unstructured":"Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 218, e20202135 (2021).","journal-title":"J. Exp. Med."},{"key":"755_CR28","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1007\/s12035-021-02347-4","volume":"58","author":"M Norouzi","year":"2021","unstructured":"Norouzi, M., Miar, P., Norouzi, S. & Nikpour, P. Nervous System Involvement in COVID-19: a review of the current knowledge. Mol. Neurobiol. 58, 3561\u20133574 (2021).","journal-title":"Mol. Neurobiol."},{"key":"755_CR29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virusres.2009.01.005","volume":"142","author":"SF Dosch","year":"2009","unstructured":"Dosch, S. F., Mahajan, S. D. & Collins, A. R. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res. 142, 19\u201327 (2009).","journal-title":"Virus Res."},{"key":"755_CR30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41590-021-00937-x","volume":"22","author":"M Zheng","year":"2021","unstructured":"Zheng, M. et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 22, 829\u2013838 (2021).","journal-title":"Nat. Immunol."},{"key":"755_CR31","doi-asserted-by":"publisher","unstructured":"Khan, S. et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kappaB pathway. bioRxiv https:\/\/doi.org\/10.1101\/2021.03.16.435700 (2021).","DOI":"10.1101\/2021.03.16.435700"},{"key":"755_CR32","doi-asserted-by":"publisher","unstructured":"Qian, Y. et al. Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01396-21 (2021).","DOI":"10.1128\/JVI.01396-21"},{"key":"755_CR33","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/brain\/awab122","volume":"144","author":"Y Xia","year":"2021","unstructured":"Xia, Y. et al. Reactive microglia enhance the transmission of exosomal alpha-synuclein via toll-like receptor 2. Brain 144, 2024\u20132037 (2021).","journal-title":"Brain"},{"key":"755_CR34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fphar.2018.00417","volume":"9","author":"IF Caplan","year":"2018","unstructured":"Caplan, I. F. & Maguire-Zeiss, K. A. Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies. Front. Pharmacol. 9, 417 (2018).","journal-title":"Front. Pharmacol."},{"key":"755_CR35","doi-asserted-by":"crossref","first-page":"eaay0399","DOI":"10.1126\/scitranslmed.aay0399","volume":"12","author":"C Kim","year":"2020","unstructured":"Kim, C. et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci. Transl. Med. 12, eaay0399 (2020).","journal-title":"Sci. Transl. Med."},{"key":"755_CR36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s12276-021-00562-6","volume":"53","author":"C Kim","year":"2021","unstructured":"Kim, C. et al. Effects of innate immune receptor stimulation on extracellular alpha-synuclein uptake and degradation by brain resident cells. Exp. Mol. Med. 53, 281\u2013290 (2021).","journal-title":"Exp. Mol. Med."},{"key":"755_CR37","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s00415-021-10406-y","volume":"268","author":"BN Harapan","year":"2021","unstructured":"Harapan, B. N. & Yoo, H. J. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J. Neurol. 268, 3059\u20133071 (2021).","journal-title":"J. Neurol."},{"key":"755_CR38","doi-asserted-by":"crossref","first-page":"e13013","DOI":"10.1111\/bpa.13013","volume":"31","author":"A Maiese","year":"2021","unstructured":"Maiese, A. et al. SARS-CoV-2 and the brain: a review of the current knowledge on neuropathology in COVID-19. Brain Pathol. 31, e13013 (2021).","journal-title":"Brain Pathol."},{"key":"755_CR39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-020-00640-3","volume":"12","author":"MT Heneka","year":"2020","unstructured":"Heneka, M. T., Golenbock, D., Latz, E., Morgan, D. & Brown, R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res. Ther. 12, 69 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"755_CR40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1474-4422(20)30308-2","volume":"19","author":"J Matschke","year":"2020","unstructured":"Matschke, J. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 19, 919\u2013929 (2020).","journal-title":"Lancet Neurol."},{"key":"755_CR41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cca.2020.05.019","volume":"508","author":"R Liu","year":"2020","unstructured":"Liu, R. et al. Decreased T cell populations contribute to the increased severity of COVID-19. Clin. Chim. Acta 508, 110\u2013114 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"755_CR42","first-page":"2000524","volume":"56","author":"RH Du","year":"2020","unstructured":"Du, R. H. et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2. Eur. Respir. J. 56, 2000524 (2020).","journal-title":"Eur. Respir. J."},{"key":"755_CR43","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.immuni.2021.06.002","volume":"54","author":"M Schwabenland","year":"2021","unstructured":"Schwabenland, M. et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity 54, 1594\u20131610 e1511 (2021).","journal-title":"Immunity"},{"key":"755_CR44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMc2019373","volume":"383","author":"IH Solomon","year":"2020","unstructured":"Solomon, I. H. et al. Neuropathological Features of Covid-19. N. Engl. J. Med. 383, 989\u2013992 (2020).","journal-title":"N. Engl. J. Med."},{"key":"755_CR45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/1073858420956905","volume":"27","author":"R Butowt","year":"2020","unstructured":"Butowt, R. & von Bartheld, C. S. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist 27, 582\u2013603 (2020).","journal-title":"Neuroscientist"},{"key":"755_CR46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","volume":"24","author":"J Meinhardt","year":"2021","unstructured":"Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 24, 168\u2013175 (2021).","journal-title":"Nat. Neurosci."},{"key":"755_CR47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jocn.2020.07.007","volume":"79","author":"D Armocida","year":"2020","unstructured":"Armocida, D., Palmieri, M., Frati, A., Santoro, A. & Pesce, A. How SARS-Cov-2 can involve the central nervous system. A systematic analysis of literature of the department of human neurosciences of Sapienza University, Italy. J. Clin. Neurosci. 79, 231\u2013236 (2020).","journal-title":"J. Clin. Neurosci."},{"key":"755_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12987-021-00267-y","volume":"18","author":"C McQuaid","year":"2021","unstructured":"McQuaid, C., Brady, M. & Deane, R. SARS-CoV-2: is there neuroinvasion? Fluids Barriers CNS 18, 32 (2021).","journal-title":"Fluids Barriers CNS"},{"key":"755_CR49","volume":"11","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nat. Commun. 11, 4400 (2020).","journal-title":"Nat. Commun."},{"key":"755_CR50","doi-asserted-by":"crossref","first-page":"e05850","DOI":"10.1016\/j.heliyon.2020.e05850","volume":"7","author":"K Sun","year":"2021","unstructured":"Sun, K., Gu, L., Ma, L. & Duan, Y. Atlas of ACE2 gene expression reveals novel insights into transmission of SARS-CoV-2. Heliyon 7, e05850 (2021).","journal-title":"Heliyon"},{"key":"755_CR51","doi-asserted-by":"publisher","unstructured":"Casagrande, M. et al. Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318618 (2021).","DOI":"10.1136\/bjophthalmol-2020-318618"},{"key":"755_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05529-x","author":"J Penkava","year":"2021","unstructured":"Penkava, J. et al. Detection of SARS-CoV-2-RNA in post-mortem samples of human eyes. Graefes Arch. Clin. Exp. Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-021-05529-x (2021).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"755_CR53","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41593-020-00771-8","volume":"24","author":"EM Rhea","year":"2021","unstructured":"Rhea, E. M. et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat. Neurosci. 24, 368\u2013378 (2021).","journal-title":"Nat. Neurosci."},{"key":"755_CR54","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/ijms22052681","volume":"22","author":"MA Erickson","year":"2021","unstructured":"Erickson, M. A., Rhea, E. M., Knopp, R. C. & Banks, W. A. Interactions of SARS-CoV-2 with the Blood-Brain Barrier. Int. J. Mol. Sci. 22, 2681 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"755_CR55","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1212\/NXI.0000000000000893","volume":"7","author":"H Alexopoulos","year":"2020","unstructured":"Alexopoulos, H. et al. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: studies in 8 stuporous and comatose patients. Neurol. Neuroimmunol. Neuroinflamm. 7, e893 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"755_CR56","doi-asserted-by":"publisher","unstructured":"Frontera, J. A. et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer\u2019s dementia. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12556 (2022).","DOI":"10.1002\/alz.12556"},{"key":"755_CR57","doi-asserted-by":"crossref","first-page":"13603","DOI":"10.3390\/ijms222413603","volume":"22","author":"L Chiricosta","year":"2021","unstructured":"Chiricosta, L., Gugliandolo, A. & Mazzon, E. SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer\u2019s Disease Patients. Int. J. Mol. Sci. 22, 13603 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"755_CR58","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3389\/fimmu.2020.01939","volume":"11","author":"K Kasparian","year":"2020","unstructured":"Kasparian, K., Graykowski, D. & Cudaback, E. Commentary: APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort. Front. Immunol. 11, 1939 (2020).","journal-title":"Front. Immunol."},{"key":"755_CR59","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"M Safieh","year":"2019","unstructured":"Safieh, M., Korczyn, A. D. & Michaelson, D. M. ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med. 17, 64 (2019).","journal-title":"BMC Med."},{"key":"755_CR60","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3233\/JAD-215161","volume":"84","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. COVID-19 Case Fatality and Alzheimer\u2019s Disease. J. Alzheimer\u2019s Dis. 84, 1447\u20131452 (2021).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"755_CR61","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jagp.2020.04.010","volume":"28","author":"EE Brown","year":"2020","unstructured":"Brown, E. E., Kumar, S., Rajji, T. K., Pollock, B. G. & Mulsant, B. H. Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer\u2019s Disease and Related Dementias. Am. J. Geriatr. Psychiatry 28, 712\u2013721 (2020).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"755_CR62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-200604","volume":"76","author":"C Boutoleau-Bretonniere","year":"2020","unstructured":"Boutoleau-Bretonniere, C. et al. The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer\u2019s Disease During the COVID-19 Crisis. J. Alzheimer\u2019s Dis. 76, 41\u201347 (2020).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"755_CR63","volume":"24","author":"W Ni","year":"2020","unstructured":"Ni, W. et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care 24, 422 (2020).","journal-title":"Crit. Care"},{"key":"755_CR64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","volume":"8","author":"PG Kehoe","year":"2016","unstructured":"Kehoe, P. G., Wong, S., Al Mulhim, N., Palmer, L. E. & Miners, J. S. Angiotensin-converting enzyme 2 is reduced in Alzheimer\u2019s disease in association with increasing amyloid-beta and tau pathology. Alzheimer\u2019s Res. Ther. 8, 50 (2016).","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"755_CR65","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jinf.2020.06.072","volume":"81","author":"KH Lim","year":"2020","unstructured":"Lim, K. H., Yang, S., Kim, S. H. & Joo, J. Y. Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer\u2019s disease. J. Infect. 81, e33\u2013e34 (2020).","journal-title":"J. Infect."},{"key":"755_CR66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5114\/fn.2021.109495","volume":"59","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y., Li, W. & Lukiw, W. Ubiquity of the SARS-CoV-2 receptor ACE2 and upregulation in limbic regions of Alzheimer\u2019s disease brain. Folia Neuropathol. 59, 232\u2013238 (2021).","journal-title":"Folia Neuropathol."},{"key":"755_CR67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3233\/JPD-202320","volume":"11","author":"C Fearon","year":"2021","unstructured":"Fearon, C. & Fasano, A. Parkinson\u2019s Disease and the COVID-19 Pandemic. J. Parkinson\u2019s Dis. 11, 431\u2013444 (2021).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"755_CR68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(20)30442-7","volume":"20","author":"M Merello","year":"2021","unstructured":"Merello, M., Bhatia, K. P. & Obeso, J. A. SARS-CoV-2 and the risk of Parkinson\u2019s disease: facts and fantasy. Lancet Neurol. 20, 94\u201395 (2021).","journal-title":"Lancet Neurol."},{"key":"755_CR69","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/PHM.0000000000001825","volume":"100","author":"MY Lee","year":"2021","unstructured":"Lee, M. Y., Oh, B. M. & Seo, H. G. Prolonged Dysphagia After a COVID-19 Infection in a Patient With Parkinson Disease. Am. J. Phys. Med. Rehabil. 100, 837\u2013839 (2021).","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"755_CR70","doi-asserted-by":"crossref","first-page":"215013272110397","DOI":"10.1177\/21501327211039709","volume":"12","author":"V Jaiswal","year":"2021","unstructured":"Jaiswal, V. et al. The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson\u2019s Disease: an updated systematic review. J. Prim. Care Community Health 12, 21501327211039709 (2021).","journal-title":"J. Prim. Care Community Health"},{"key":"755_CR71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acschemneuro.1c00666","volume":"13","author":"SA Semerdzhiev","year":"2022","unstructured":"Semerdzhiev, S. A., Fakhree, M. A. A., Segers-Nolten, I., Blum, C. & Claessens, M. Interactions between SARS-CoV-2 N-Protein and alpha-Synuclein Accelerate Amyloid Formation. ACS Chem. Neurosci. 13, 143\u2013150 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"755_CR72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JPD-202038","volume":"10","author":"RC Helmich","year":"2020","unstructured":"Helmich, R. C. & Bloem, B. R. The Impact of the COVID-19 Pandemic on Parkinson\u2019s Disease: Hidden Sorrows and Emerging Opportunities. J. Parkinson\u2019s Dis. 10, 351\u2013354 (2020).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"755_CR73","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3233\/JPD-181489","volume":"8","author":"T Ellis","year":"2018","unstructured":"Ellis, T. & Rochester, L. Mobilizing Parkinson\u2019s disease: the future of exercise. J. Parkinson\u2019s Dis. 8, S95\u2013S100 (2018).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"755_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.irn.2019.06.003","volume":"147","author":"X Xu","year":"2019","unstructured":"Xu, X., Fu, Z. & Le, W. Exercise and Parkinson\u2019s disease. Int. Rev. Neurobiol. 147, 45\u201374 (2019).","journal-title":"Int. Rev. Neurobiol."},{"key":"755_CR75","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/mds.28766","volume":"36","author":"M Kainaga","year":"2021","unstructured":"Kainaga, M., Shirota, Y., Kodama, S., Toda, T. & Hamada, M. Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson\u2019s Disease: an observational study. Mov. Disord. 36, 2461\u20132463 (2021).","journal-title":"Mov. Disord."},{"key":"755_CR76","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2015.12.005","volume":"158","author":"Y Wang","year":"2016","unstructured":"Wang, Y., Song, E., Bai, B. & Vanhoutte, P. M. Toll-like receptors mediating vascular malfunction: lessons from receptor subtypes. Pharmacol. Ther. 158, 91\u2013100 (2016).","journal-title":"Pharmacol. Ther."},{"key":"755_CR77","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.str.2011.02.004","volume":"19","author":"I Botos","year":"2011","unstructured":"Botos, I., Segal, D. M. & Davies, D. R. The structural biology of Toll-like receptors. Structure 19, 447\u2013459 (2011).","journal-title":"Structure"},{"key":"755_CR78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014).","journal-title":"Front. Immunol."},{"key":"755_CR79","doi-asserted-by":"crossref","first-page":"672395","DOI":"10.1155\/2010\/672395","volume":"2010","author":"AM Piccinini","year":"2010","unstructured":"Piccinini, A. M. & Midwood, K. S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, 672395 (2010).","journal-title":"Mediators Inflamm."},{"key":"755_CR80","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.immuni.2008.07.007","volume":"29","author":"MS Jin","year":"2008","unstructured":"Jin, M. S. & Lee, J. O. Structures of the toll-like receptor family and its ligand complexes. Immunity 29, 182\u2013191 (2008).","journal-title":"Immunity"},{"key":"755_CR81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tins.2011.02.005","volume":"34","author":"E Okun","year":"2011","unstructured":"Okun, E., Griffioen, K. J. & Mattson, M. P. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 34, 269\u2013281 (2011).","journal-title":"Trends Neurosci."},{"key":"755_CR82","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.4049\/jimmunol.181.10.7254","volume":"181","author":"M Jana","year":"2008","unstructured":"Jana, M., Palencia, C. A. & Pahan, K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer\u2019s disease. J. Immunol. 181, 7254\u20137262 (2008).","journal-title":"J. Immunol."},{"key":"755_CR83","volume":"8","author":"JT Yu","year":"2011","unstructured":"Yu, J. T., Mou, S. M., Wang, L. Z., Mao, C. X. & Tan, L. Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer\u2019s disease. J. Neuroinflammation 8, 136 (2011).","journal-title":"J. Neuroinflammation"},{"key":"755_CR84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12017-015-8376-4","volume":"18","author":"M Rezazadeh","year":"2016","unstructured":"Rezazadeh, M. et al. Genetic Factors Affecting Late-Onset Alzheimer\u2019s Disease Susceptibility. Neuromol. Med. 18, 37\u201349 (2016).","journal-title":"Neuromol. Med."},{"key":"755_CR85","doi-asserted-by":"crossref","first-page":"11982","DOI":"10.1523\/JNEUROSCI.3158-09.2009","volume":"29","author":"EG Reed-Geaghan","year":"2009","unstructured":"Reed-Geaghan, E. G., Savage, J. C., Hise, A. G. & Landreth, G. E. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci. 29, 11982\u201311992 (2009).","journal-title":"J. Neurosci."},{"key":"755_CR86","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1074\/jbc.M508125200","volume":"281","author":"K Chen","year":"2006","unstructured":"Chen, K. et al. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J. Biol. Chem. 281, 3651\u20133659 (2006).","journal-title":"J. Biol. Chem."},{"key":"755_CR87","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbi.2016.07.143","volume":"58","author":"CL McDonald","year":"2016","unstructured":"McDonald, C. L. et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer\u2019s disease. Brain Behav. Immun. 58, 191\u2013200 (2016).","journal-title":"Brain Behav. Immun."},{"key":"755_CR88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neurobiolaging.2018.06.020","volume":"70","author":"HG Pourbadie","year":"2018","unstructured":"Pourbadie, H. G. et al. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer\u2019s disease-related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiol. Aging 70, 203\u2013216 (2018).","journal-title":"Neurobiol. Aging"},{"key":"755_CR89","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1523\/JNEUROSCI.1146-08.2008","volume":"28","author":"KL Richard","year":"2008","unstructured":"Richard, K. L., Filali, M., Prefontaine, P. & Rivest, S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer\u2019s disease. J. Neurosci. 28, 5784\u20135793 (2008).","journal-title":"J. Neurosci."},{"key":"755_CR90","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.1001765","volume":"185","author":"P Vollmar","year":"2010","unstructured":"Vollmar, P. et al. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2\/4-dependent activation of the innate immune system. J. Immunol. 185, 6338\u20136347 (2010).","journal-title":"J. Immunol."},{"key":"755_CR91","first-page":"90","volume":"2","author":"KJ Doorn","year":"2014","unstructured":"Doorn, K. J. et al. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson\u2019s disease patients. Acta Neuropathol. Commun. 2, 90 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"755_CR92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neulet.2009.01.075","volume":"453","author":"S Frank","year":"2009","unstructured":"Frank, S., Copanaki, E., Burbach, G. J., Muller, U. C. & Deller, T. Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice. Neurosci. Lett. 453, 41\u201344 (2009).","journal-title":"Neurosci. Lett."},{"key":"755_CR93","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-4159.2007.05001.x","volume":"104","author":"ML Udan","year":"2008","unstructured":"Udan, M. L., Ajit, D., Crouse, N. R. & Nichols, M. R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem. 104, 524\u2013533 (2008).","journal-title":"J. Neurochem."},{"key":"755_CR94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2017.07.014","volume":"656","author":"X Li","year":"2017","unstructured":"Li, X., Xue, L., Sun, J., Sun, Y. & Xie, A. Single nucleotide polymorphisms in the toll-like receptor 2 (TLR2) gene are associated with sporadic Parkinson\u2019s disease in the North-eastern Han Chinese population. Neurosci. Lett. 656, 72\u201376 (2017).","journal-title":"Neurosci. Lett."},{"key":"755_CR95","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10072-012-1106-x","volume":"34","author":"K Kalinderi","year":"2013","unstructured":"Kalinderi, K., Bostantjopoulou, S., Katsarou, Z. & Fidani, L. TLR9 -1237 T\/C and TLR2 -194 to -174 del polymorphisms and the risk of Parkinson\u2019s disease in the Greek population: a pilot study. Neurol. Sci. 34, 679\u2013682 (2013).","journal-title":"Neurol. Sci."},{"key":"755_CR96","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5607\/en.2016.25.3.113","volume":"25","author":"C Kim","year":"2016","unstructured":"Kim, C., Lee, H. J., Masliah, E. & Lee, S. J. Non-cell-autonomous Neurotoxicity of alpha-synuclein Through Microglial Toll-like Receptor 2. Exp. Neurobiol. 25, 113\u2013119 (2016).","journal-title":"Exp. Neurobiol."},{"key":"755_CR97","doi-asserted-by":"crossref","first-page":"e79160","DOI":"10.1371\/journal.pone.0079160","volume":"8","author":"C Roodveldt","year":"2013","unstructured":"Roodveldt, C. et al. Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS ONE 8, e79160 (2013).","journal-title":"PLoS ONE"},{"key":"755_CR98","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/WNR.0000000000000406","volume":"26","author":"H Qiao","year":"2015","unstructured":"Qiao, H. et al. Elevated neuronal alpha-synuclein promotes microglia activation after spinal cord ischemic\/reperfused injury. NeuroReport 26, 656\u2013661 (2015).","journal-title":"NeuroReport"},{"key":"755_CR99","doi-asserted-by":"crossref","first-page":"ra45","DOI":"10.1126\/scisignal.2005965","volume":"8","author":"SG Daniele","year":"2015","unstructured":"Daniele, S. G. et al. Activation of MyD88-dependent TLR1\/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal 8, ra45 (2015).","journal-title":"Sci. Signal"},{"key":"755_CR100","volume":"20","author":"NH Kim","year":"2020","unstructured":"Kim, N. H. et al. Toll-like receptor 2 downregulation and cytokine dysregulation predict mortality in patients with Staphylococcus aureus bacteremia. BMC Infect. Dis. 20, 901 (2020).","journal-title":"BMC Infect. Dis."},{"key":"755_CR101","doi-asserted-by":"crossref","first-page":"pyu103","DOI":"10.1093\/ijnp\/pyu103","volume":"18","author":"J Drouin-Ouellet","year":"2014","unstructured":"Drouin-Ouellet, J. et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson\u2019s disease. Int. J. Neuropsychopharmacol. 18, pyu103 (2014).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"755_CR102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbi.2018.02.012","volume":"69","author":"P La Vitola","year":"2018","unstructured":"La Vitola, P. et al. Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain Behav. Immun. 69, 591\u2013602 (2018).","journal-title":"Brain Behav. Immun."},{"key":"755_CR103","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuroscience.2017.05.016","volume":"356","author":"JH Koo","year":"2017","unstructured":"Koo, J. H. et al. Treadmill exercise produces neuroprotective effects in a murine model of Parkinson\u2019s disease by regulating the TLR2\/MyD88\/NF-kappaB signaling pathway. Neuroscience 356, 102\u2013113 (2017).","journal-title":"Neuroscience"},{"key":"755_CR104","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12264-014-1445-5","volume":"30","author":"HY Liu","year":"2014","unstructured":"Liu, H. Y., Chen, C. Y. & Hsueh, Y. P. Innate immune responses regulate morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons. Neurosci. Bull. 30, 645\u2013654 (2014).","journal-title":"Neurosci. Bull."},{"key":"755_CR105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.celrep.2015.09.044","volume":"13","author":"C Kim","year":"2015","unstructured":"Kim, C. et al. Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep. 13, 771\u2013782 (2015).","journal-title":"Cell Rep."},{"key":"755_CR106","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"N Dzamko","year":"2017","unstructured":"Dzamko, N. et al. Toll-like receptor 2 is increased in neurons in Parkinson\u2019s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 133, 303\u2013319 (2017).","journal-title":"Acta Neuropathol."},{"key":"755_CR107","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis, L. alpha-Synuclein in Parkinson\u2019s disease. Cold Spring Harb. Perspect. Med. 2, a009399 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"755_CR108","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cellsig.2013.12.016","volume":"26","author":"L Fang","year":"2014","unstructured":"Fang, L., Wu, H. M., Ding, P. S. & Liu, R. Y. TLR2 mediates phagocytosis and autophagy through JNK signaling pathway in Staphylococcus aureus-stimulated RAW264.7 cells. Cell. Signal. 26, 806\u2013814 (2014).","journal-title":"Cell. Signal."},{"key":"755_CR109","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.79.20.12658-12666.2005","volume":"79","author":"JP Wang","year":"2005","unstructured":"Wang, J. P. et al. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J. Virol. 79, 12658\u201312666 (2005).","journal-title":"J. Virol."},{"key":"755_CR110","doi-asserted-by":"crossref","first-page":"e54586","DOI":"10.1371\/journal.pone.0054586","volume":"8","author":"M Cai","year":"2013","unstructured":"Cai, M. et al. The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-kappaB through the Toll-like receptor 2 and MyD88\/TRAF6-dependent signaling pathway. PLoS ONE 8, e54586 (2013).","journal-title":"PLoS ONE"},{"key":"755_CR111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.02.007","volume":"128","author":"W Wang","year":"2007","unstructured":"Wang, W. et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res. 128, 1\u20138 (2007).","journal-title":"Virus Res."},{"key":"755_CR112","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/jmv.26826","volume":"93","author":"S Khanmohammadi","year":"2021","unstructured":"Khanmohammadi, S. & Rezaei, N. Role of Toll-like receptors in the pathogenesis of COVID-19. J. Med. Virol. 93, 2735\u20132739 (2021).","journal-title":"J. Med. Virol."},{"key":"755_CR113","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbi.2021.12.007","volume":"100","author":"MG Frank","year":"2021","unstructured":"Frank, M. G. et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties. Brain Behav. Immun. 100, 267\u2013277 (2021).","journal-title":"Brain Behav. Immun."},{"key":"755_CR114","doi-asserted-by":"crossref","first-page":"103153","DOI":"10.1016\/j.ebiom.2020.103153","volume":"63","author":"PC Proud","year":"2021","unstructured":"Proud, P. C. et al. Prophylactic intranasal administration of a TLR2\/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. EBioMedicine 63, 103153 (2021).","journal-title":"EBioMedicine"},{"key":"755_CR115","first-page":"133","volume":"325","author":"HK Koh","year":"2021","unstructured":"Koh, H. K., Geller, A. C. & VanderWeele, T. J. Deaths From COVID-19. JAMA 325, 133\u2013134 (2021).","journal-title":"JAMA"},{"key":"755_CR116","doi-asserted-by":"crossref","first-page":"592214","DOI":"10.3389\/fncel.2020.592214","volume":"14","author":"ME Tremblay","year":"2020","unstructured":"Tremblay, M. E., Madore, C., Bordeleau, M., Tian, L. & Verkhratsky, A. Neuropathobiology of COVID-19: the role for Glia. Front. Cell. Neurosci. 14, 592214 (2020).","journal-title":"Front. Cell. Neurosci."},{"key":"755_CR117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","volume":"60","author":"A Varatharaj","year":"2017","unstructured":"Varatharaj, A. & Galea, I. The blood-brain barrier in systemic inflammation. Brain Behav. Immun. 60, 1\u201312 (2017).","journal-title":"Brain Behav. Immun."},{"key":"755_CR118","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-022-00755-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-022-00755-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-022-00755-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T20:09:15Z","timestamp":1700424555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-022-00755-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":118,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s12276-022-00755-7","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}